, opens new tab on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) , opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S ...
The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B.
The biotech company said it would develop a combination Covid and flu shot with Sanofi as part of a billion-dollar deal.
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Novavax (NVAX) stock reaches a 52-week high as a licensing deal with Sanofi (SNY) prompts J.P. Morgan and Bank of America to ...
GXO Opens up New Distribution Hub for Conair <li /> Sinclair Ponders Unloading Stations <li /> AMC Plunges on Q1 Figures <li ...
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine.
With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race to ...
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.